The science, as it stands.

Japanese researcher Shimizu Kuniyoshi published a study on how Reishi mushroom (Ganoderma lingzhi) affects menopausal symptoms. Published in a Japanese healthcare journal specialising in menopause and ageing, the study reported improvements in menopausal complaints among participants taking Reishi. This is one of very few studies globally that directly examines the relationship between a medicinal mushroom and menopausal symptoms — a topic of significant consumer interest that remains largely unstudied in Western research.

Researchers at Kyushu Nutrition Welfare University studied whether Lion's Mane mushroom could improve sleep quality in university students. The study measured sleep parameters before and after supplementation and reported improvements in both sleep onset and overall sleep quality. This is one of very few human studies directly testing Lion's Mane for sleep — a topic where clinical research remains scarce despite strong consumer interest.

Researchers Shimizu, Nagano, and Hayashi tested whether Lion's Mane mushroom (Yamabushitake) could improve common health complaints in middle-aged women. The study specifically targeted "indefinite complaints" — the broad category of symptoms including fatigue, mood changes, and physical discomfort that many women experience during midlife. The researchers reported measurable improvements. This is one of the only studies anywhere in the world that specifically tests Lion's Mane in middle-aged women.

Dr. Otomo Eiichi published clinical observations on the effects of Lion's Mane fruiting body in patients with Alzheimer's-type senile dementia. Published in the Japanese journal Geriatric Medicine, the study documented clinical outcomes in dementia patients who consumed Lion's Mane as a food supplement. This is one of the earliest Japanese clinical reports directly linking Lion's Mane consumption to outcomes in diagnosed Alzheimer's patients — predating much of the Western research on this topic.

Comprehensive review examining beta-glucan structure-activity relationships across medicinal mushroom species. Key finding: branching frequency and molecular weight (optimum ~200kDa) are critical determinants of immunological activity. The authors discuss implications for extraction methodology and standardisation.

Systematic review of immunomodulatory effects of G. lucidum polysaccharides. Key findings: enhanced phagocytic activity, increased IL-2 and IFN-γ production, and NK cell potentiation. Beta-glucan content and molecular weight significantly influence biological activity.

Narrative review synthesising published research on H. erinaceus. Bioactive compounds categorised: erinacines (diterpenes from mycelium), hericenones (aromatic compounds from fruiting body), polysaccharides, and lectins. Covers neurotropic, immunomodulatory, antitumour, antioxidant, and antimicrobial activity.

Systematic review of in vitro antioxidant studies. Ganoderic acids A, B, and C identified as primary contributors, particularly in lipophilic oxidative environments. Polysaccharides contribute through hydroxyl radical scavenging. Extraction method significantly influences compound profile and measured activity.

Researchers compiled 26 studies on Lion's Mane as a supplement — including five randomised controlled trials, three pilot clinical trials, and 15 laboratory studies — published between 2000 and 2024. Across the human trials, dosages ranged from 1.0 to 3.2 grams per day. Cognitive scores showed modest improvement on standardised tests. Side effects were generally mild (stomach discomfort, headache), though one case report documented a serious allergic reaction. The authors concluded the evidence is promising but called for larger, longer trials.

Researchers isolated erinacine S — a diterpenoid compound from Lion's Mane — and tested it against chemotherapy-resistant colorectal cancer cells in the laboratory. The compound triggered programmed cell death through multiple pathways simultaneously and reduced markers associated with cancer stem cells, the subpopulation responsible for treatment resistance and tumour regrowth. While this is early-stage laboratory research, it targets one of the hardest problems in cancer biology: the cells that survive conventional treatment.

Researchers at the Medical University of Lublin (Poland) reviewed the published evidence on Turkey Tail mushroom (Coriolus versicolor) and breast cancer specifically. The review compiled laboratory, animal, and human study data showing Turkey Tail's polysaccharopeptides — PSK and PSP — may enhance immune function and inhibit tumour growth through multiple pathways. The authors noted that Turkey Tail is already used as an adjunct cancer therapy in Japan and China, and argued that the existing evidence warrants more clinical trials in Western oncology settings. This is a review — it synthesises existing research rather than presenting new experimental data.

A 2025 comprehensive review examined the full scope of Reishi mushroom research — from its chemistry (polysaccharides, triterpenoids, phenolic compounds) to its therapeutic applications across cancer, immune function, cardiovascular health, neuroprotection, and antioxidant activity. The review also addressed safety, noting that while Reishi is generally well-tolerated, quality control varies widely across commercial products. The authors highlighted that despite centuries of traditional use and a growing body of modern research, more rigorous clinical trials are needed to confirm specific health benefits. This is the most up-to-date overview of Reishi science as of 2025.

A 2025 review compiled the latest research on Lion's Mane polysaccharides and their effects on the gastrointestinal system, immune function, and neuroprotection. The authors traced how these compounds interact with gut bacteria, modulate inflammatory responses, and may support nerve health through the gut-brain axis.

This 2024 overview brings together everything currently known about Lion's Mane — from cultivation conditions (25-30°C, sporulation stops above 33°C) to its two key compound families: hericenones from the fruiting body and erinacines from the mycelium. Both stimulate nerve growth factor production, but through different mechanisms.

Lion's Mane mushroom contains two families of compounds — hericenones in the fruiting body and erinacines in the mycelium — that researchers have linked to nerve growth factor (NGF) production. In a 2023 review, Polish researchers catalogued the specific potency of individual erinacines in stimulating NGF synthesis in mouse brain cells, and highlighted human studies where older adults with mild cognitive impairment showed improved cognitive function after 12 to 16 weeks of supplementation. Researchers also reported that feeding Lion's Mane to mice for seven days increased NGF gene expression fivefold in the hippocampus. The reviewers noted that variability in these compounds across cultivation conditions remains a significant challenge for reproducing results in clinical settings.

Researchers traced the full evidence chain for Lion's Mane and neurological disease — from laboratory findings showing how hericenones and erinacines stimulate nerve growth factor, through animal models demonstrating brain protection, to the small number of human trials reporting cognitive improvements. The review concluded that Lion's Mane shows genuine promise for neuroprotection but emphasised the gap between strong preclinical data and limited human evidence. For anyone following this science: the animal data is compelling, the human data is early.

Researchers reviewed eight different extraction methods for mushroom polysaccharides — the compounds responsible for most of the immune and health effects of Lion's Mane and Reishi. The key finding: more aggressive techniques pull more material but degrade the very compounds responsible for biological activity. Gentler approaches — enzyme-assisted, lower temperatures — retain more of the original molecular structure that makes mushrooms medicinally interesting.

Polish researchers reviewed how Lion's Mane and Turkey Tail mushroom extracts have been used in supportive cancer care. They noted that Turkey Tail's PSK polysaccharide was approved as an anticancer drug in Japan in 1977 and is routinely used in oncology there. For Lion's Mane, only two small human studies (each with 30 participants) existed at the time of writing, and the authors called for randomised studies in larger groups of patients receiving chemotherapy. They also flagged important safety considerations: commercially available supplements range from 100 to 1,000 milligrams per dose with no officially established daily dose, they are contraindicated in pregnant or lactating women and children under three, and immunomodulatory extracts should not be used in organ transplant recipients due to the risk of graft rejection.

Lion's Mane polysaccharides have been studied across a remarkably wide range of health areas — immune modulation, neuroprotection, antioxidant activity, gut health, and anti-cancer effects. This comprehensive review in a top-tier food science journal maps the extraction methods, molecular structures, and biological activities. The consistent finding across studies: different polysaccharide fractions produce different biological effects, which is why how a mushroom is extracted determines what it can do.

Researchers at the University of Hong Kong reviewed the preclinical and clinical evidence on whether Lion's Mane mushroom could help with depression. In animal studies, mice given erinacine A-enriched extract for four weeks showed activation of BDNF pathways and reduced inflammatory markers linked to depressive behaviour. In the only human study directly addressing mood, 30 women (average age 41) who ate Lion's Mane cookies daily for four weeks reported reduced feelings of depression, anxiety, and frustration — though the reviewers noted this was a small, gender-specific sample. The authors concluded that Lion's Mane compounds appear to work through nerve growth factor and anti-inflammatory pathways, but emphasised the research is still at an early stage and larger human trials are needed.

Lion's Mane polysaccharides have been studied for immune support, nerve protection, gut healing, and anti-tumour activity. Notably, this review documents that China's food and drug authority has approved Lion's Mane extract as a treatment for chronic gastritis — one of the few direct pharmaceutical approvals for a medicinal mushroom worldwide. The review also identifies that hericenones C, D, and E specifically failed to increase nerve growth factor in certain cell lines — an important nuance often overlooked.

Researchers studied how Reishi polysaccharides affect human immune cells at the genetic level. They found the mushroom extract activated 17 specific immune-related genes in monocytic leukaemia cells — genes involved in the body's anti-tumour and anti-microbial defence systems. The study provides a molecular map of how Reishi talks to the immune system, showing it doesn't just 'boost' immunity in a vague way but activates specific, identifiable pathways.

Researchers explored how erinacines from Lion's Mane interact with microglia — the brain's own immune cells that become overactivated in Alzheimer's disease. The study found that erinacines calmed the inflammatory response of these cells while preserving their ability to clear harmful amyloid deposits. This dual action — reducing brain inflammation without shutting down the cleanup crew — is exactly what Alzheimer's researchers have been looking for, and it adds specific mechanistic evidence for why Lion's Mane compounds keep showing up in neurodegeneration studies.

Researchers at the University of Pavia studied whether Lion's Mane could protect ageing brains by working through the gut. They gave elderly frail mice a daily oral dose of Lion's Mane extract for two months. The treated mice showed dramatically reduced brain inflammation — CD45 microglia dropped significantly, GFAP astrocytes fell, and IL-6 (an inflammatory marker) decreased. Their gut bacteria shifted too: inflammation-linked species decreased while cognition-associated species increased. Treated mice also showed improved recognition memory.

Researchers in Taiwan tested whether erinacine A-enriched Lion's Mane mycelium could extend lifespan and protect brain health in Drosophila — a model organism widely used in ageing research. The flies receiving Lion's Mane lived significantly longer and showed better preservation of motor function and neural integrity as they aged. The study identified specific neuroprotective molecular pathways activated by erinacine A, adding to the growing evidence that this compound may genuinely slow age-related neural decline.

Researchers in China identified a specific Lion's Mane compound — 3-hydroxyhericenone F — as a potential inhibitor of beta-secretase (BACE1), an enzyme involved in amyloid plaque formation studied in Alzheimer's research. Using computer modelling to screen Lion's Mane compounds, they found 3-hydroxyhericenone F ranked highest against the enzyme target. In laboratory cell tests, the compound significantly reduced BACE1 expression and lowered levels of phosphorylated Tau and amyloid-beta proteins. The researchers then tested Lion's Mane extracts in rats with chemically induced cognitive decline: after eight weeks, rats given a high dose (100 mg/kg daily) of an ethanol-water extract showed measurably improved learning and memory in maze tests, with reduced Alzheimer's-associated markers in a dose-dependent pattern.

Researchers at National Yang-Ming University and Grape King Bio in Taiwan tested whether Lion's Mane mycelium enriched with erinacine A could reduce Alzheimer's-related brain changes in transgenic mice bred to develop the disease. After 30 days of daily oral doses, the ethanol extract cut amyloid plaque burden by 56% and plaque count by 44%. It also reduced the brain's inflammatory response — fewer activated microglia and astrocytes clustering around plaques — while boosting levels of insulin-degrading enzyme (which clears amyloid) and nerve growth factor. Mice treated for 81 days recovered lost daily-living behaviors like nest building. The results point to erinacine A from Lion's Mane mycelium as a candidate worth investigating for Alzheimer's prevention, though this is animal research and human trials are needed.

In a landmark 2011 animal study, researchers tested whether Lion's Mane mushroom extract could speed up nerve repair after a crush injury to the peroneal nerve in rats. Animals given daily oral Lion's Mane extract showed significantly faster nerve regeneration compared to controls — the damaged nerves recovered function more quickly, with measurable improvements in both nerve structure and muscle response. This study is frequently cited as foundational evidence for Lion's Mane's potential in nerve repair, and is directly relevant to anyone interested in recovery from peripheral nerve injuries.

Aqueous H. erinaceus extract administered daily following peroneal nerve crush injury in rats. Functional recovery assessed via toe spread reflex and walking track analysis. Histological examination confirmed enhanced axonal regeneration and remyelination in the treatment group.

H. erinaceus aqueous extract applied to 1321N1 human astrocytoma cells showed dose-dependent increases in NGF mRNA expression and protein secretion. Active compounds responsible are thought to include hericenones and erinacines.

The way a mushroom is extracted changes what ends up in the product. Researchers found that steam explosion pretreatment dramatically increased the yield of beneficial polysaccharides from Lion's Mane — by nearly 245%. The treated extracts also produced more short-chain fatty acids during gut fermentation tests, suggesting better bioavailability. For consumers, this means extraction method directly affects what your body actually receives.

Researchers investigated how ganoderic acid DM — a specific triterpenoid compound from Reishi mushroom — protects against breast cancer cell growth in the laboratory. The study mapped the molecular pathway through which this compound triggers cancer cell death (apoptosis) while leaving healthy cells largely unaffected. Ganoderic acid DM was shown to regulate specific signalling pathways involved in breast cancer progression. This is laboratory research, not a clinical trial, but it adds mechanistic evidence for why Reishi compounds are being studied in breast cancer contexts.

Researchers at Peking Union Medical College mapped the gene networks that Reishi regulates in colorectal cancer cells. They found the mushroom extract switches specific genes on and off in patterns that inhibit cancer cell growth — providing a molecular blueprint of how Reishi interacts with cancer biology at the cellular level. Understanding mechanism is the first step toward clinical application.

Researchers optimised a gentler extraction method — ultrasound instead of high heat — to recover erinacine A from Lion's Mane mycelium alongside antioxidant polyphenols. The method achieved strong compound recovery without the high temperatures that can destroy heat-sensitive bioactives. This matters because erinacine A is one of the most studied Lion's Mane compounds for brain health, and how it's extracted determines whether it survives into the final product.

Researchers purified a specific sterol compound from Reishi mycelium and tested it against human melanoma cells. The compound was highly selective — killing cancer cells at low concentrations while leaving healthy cells largely unharmed. The mechanism worked through the mitochondrial pathway, activating specific caspases that trigger programmed cell death. This is laboratory research, not a clinical trial, but the selectivity is what makes it noteworthy.

Researchers compared two extraction techniques for recovering beta-glucans from mushrooms — microwave-assisted and pressurised liquid extraction. Both preserved the structural character of the polysaccharides, confirming that more advanced methods can extract effectively without destroying the compounds that matter. Importantly, temperatures above 190°C caused breakdown — a clear ceiling that responsible extraction protocols need to respect.

A team of Spanish and Japanese researchers found the optimal conditions for extracting beta-glucans from Reishi: 158°C with a controlled flow rate, producing over 60% beta-glucan content in the extract. Too hot and the valuable compounds degrade. Too cool and they don't release. The study maps the exact temperature boundary — critical knowledge for anyone making or buying Reishi extracts.

Researchers tested whether combining Turkey Tail and Reishi extracts would be more effective against leukaemia cells than either alone. The combination was indeed more potent — and ethanolic extracts outperformed water extracts significantly. This finding is directly relevant to dual-extraction methodology: the ethanol phase captures compounds that water alone misses, and the combination of two mushroom species may offer effects that neither provides individually.

Researchers at Zhejiang Chinese Medical University used computational pharmacology to map exactly how Reishi mushroom might help with insomnia. They screened 80 active compounds in Reishi and found 34 with sedative-hypnotic potential, five of which can cross the blood-brain barrier. These compounds collectively target 51 genes linked to insomnia — with TNF (an inflammation regulator) being the most connected target, influenced by 15 different Reishi compounds. Beta-sitosterol emerged as the standout compound: it crosses the blood-brain barrier effectively and connects to 37 target genes. The analysis shows Reishi works through both central brain pathways (pineal gland, amygdala, prefrontal cortex) and peripheral organs (heart, thyroid, liver) simultaneously — a multi-system approach that conventional sleeping pills lack.

A systematic review by researchers at Liverpool Hope University pulled together all available evidence on Lion's Mane and Alzheimer's disease — 16 studies in total, including 3 human clinical trials and 13 animal studies. Across the board, Lion's Mane supplementation produced statistically significant improvements in cognitive behavior, brain biochemistry, and Alzheimer's-related brain pathology compared to controls. In animal models, it reduced amyloid plaque buildup, boosted nerve growth factor, and calmed overactivated brain immune cells. The review singles out erinacine-A as the compound most likely responsible. The authors stress that more human clinical trials are essential, but the existing evidence makes a compelling case for Lion's Mane as a candidate for Alzheimer's prevention research.